{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:28:51Z","timestamp":1794266931868,"version":"4.9.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2024.116128","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T01:21:24Z","timestamp":1704763284000},"page":"116128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization"],"prefix":"10.1016","volume":"266","author":[{"given":"Tania","family":"Ciaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Vestuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Di Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Musella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardina","family":"Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Giovanna","family":"Basilicata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Novi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Capolupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bifulco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Campiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gomez-Monterrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Manfra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Ostacolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-6276","authenticated-orcid":false,"given":"Alessia","family":"Bertamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116128_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116128_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.750378","article-title":"More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review","volume":"8","author":"Hayes","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2024.116128_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116128_bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116128_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116128_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s15010-020-01557-7","article-title":"Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence","volume":"49","author":"Lin","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.ejmech.2024.116128_bib8","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1093\/cid\/ciac600","volume":"76","author":"Li","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116128_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00044-021-02841-3","article-title":"Review on molnupiravir as a promising oral drug for the treatment of COVID-19","volume":"31","author":"Zarenezhad","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.116128_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2024.116128_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/antib12010005","article-title":"A Review of the currently available antibody therapy for the treatment of coronavirus disease 2019 (COVID-19)","volume":"12","author":"Widyasari","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2024.116128_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79639","article-title":"Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern","volume":"11","author":"Mazzaferri","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2024.116128_bib13","first-page":"E162","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116128_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejmech.2024.116128_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2024.116128_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/v15010167","article-title":"A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies","volume":"15","author":"Chatterjee","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2024.116128_bib18","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1080\/07391102.2022.2095305","article-title":"Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies","volume":"41","author":"Giron","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2024.116128_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710091","article-title":"Effect of delta and omicron mutations on the RBD-SD1 domain of the spike protein in SARS-CoV-2 and the omicron mutations on RBD-ACE2 interface complex","volume":"23","author":"Ching","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116128_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116128_bib21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS\u2010CoV\u20102: genomics, transmissibility, and responses to current COVID\u201019 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2024.116128_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/d41586-022-02806-5","article-title":"Omicron-specific vaccines protect as much as current jabs","volume":"609","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116128_bib24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116128_bib25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","article-title":"Potential SARS-CoV-2 main protease inhibitors","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116128_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.819165","article-title":"Targeting SARS-CoV-2 proteases for COVID-19 antiviral development","volume":"9","author":"Lv","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s43094-022-00423-7","article-title":"Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)","volume":"8","author":"Katre","year":"2022","journal-title":"Futur J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2024.116128_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114857","article-title":"Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2","volume":"244","author":"Di Micco","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.589505","article-title":"Cathepsin L in COVID-19: from pharmacological evidences to genetics","volume":"10","author":"Gomes","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116128_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116128_bib31","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1021\/acs.jmedchem.1c01494","article-title":"Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L","volume":"65","author":"Ashhurst","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105655","article-title":"Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection","volume":"216","author":"Milan Bonotto","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116128_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173499","article-title":"Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2","volume":"885","author":"Madadlou","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116128_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.116128_bib35","article-title":"MPI8 is potent against SARS\u2010CoV\u20102 by inhibiting dually and selectively the SARS\u2010CoV\u20102 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116128_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111779","article-title":"Structural and biochemical analysis of the dual inhibition of MG-132 against SARS-CoV-2 main protease (Mpro\/3CLpro) and human cathepsin-L","volume":"22","author":"Costanzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116128_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113863","article-title":"Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization","volume":"226","author":"Di Sarno","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib38","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/molecules25030698","article-title":"A review of small molecule inhibitors and functional probes of human cathepsin L","volume":"25","author":"Dana","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116128_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bmcl.2018.11.019","article-title":"Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments","volume":"29","author":"Chowdhury","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116128_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/jm701190v","article-title":"Exploring inhibitor binding at the S\u2032 subsites of cathepsin L","volume":"51","author":"Chowdhury","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-5793(97)00216-0","article-title":"The crystal structure of human cathepsin L complexed with E\u201064","volume":"407","author":"Fujishima","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.116128_bib42","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105606","article-title":"Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2","volume":"214","author":"Li","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116128_bib44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s11224-022-02089-6","article-title":"Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by molecular dynamics simulations","volume":"34","author":"Parmar","year":"2022","journal-title":"Struct. Chem."},{"key":"10.1016\/j.ejmech.2024.116128_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.07.025","article-title":"Hepatic clearance concepts and misconceptions: why the well-stirred model is still used even though it is not physiologic reality?","volume":"169","author":"Pang","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116128_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/adt.2007.103","article-title":"An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion","volume":"6","author":"McNaney","year":"2008","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2024.116128_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/17425255.3.2.149","article-title":"Stereoselectivity in drug metabolism","volume":"3","author":"Lu","year":"2007","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.116128_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpha.2015.12.004","article-title":"Significance and challenges of stereoselectivity assessing methods in drug metabolism","volume":"6","author":"Shen","year":"2016","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ejmech.2024.116128_bib49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.abe5960","article-title":"Will SARS-CoV-2 become endemic?","volume":"370","author":"Shaman","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116128_bib50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/d41586-022-00155-x","article-title":"COVID-19: endemic doesn't mean harmless","volume":"601","author":"Katzourakis","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116128_bib51","series-title":"Encyclopedia of Virology","first-page":"428","article-title":"Human coronavirus-229e, -OC43, -NL63, and -HKU1 (Coronaviridae)","author":"Liu","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116128_bib52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/anie.201006781","article-title":"Systematic investigation of halogen bonding in protein\u2013ligand interactions","volume":"50","author":"Hardegger","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2024.116128_bib53","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116128_bib54","series-title":"Schr\u00f6dinger Release 2022-3: Protein Preparation Wizard; Epik - Impact - Prime","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116128_bib55","series-title":"Schr\u00f6dinger Release 2022-3","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116128_bib56","series-title":"Schr\u00f6dinger Release 2022-3: Glide","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116128_bib57","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/foods9101415","article-title":"The influence of peptidases in intestinal brush border membranes on the absorption of oligopeptides from whey protein hydrolysate: an ex vivo study using an Ussing chamber","volume":"9","author":"Ozorio","year":"2020","journal-title":"Foods"},{"key":"10.1016\/j.ejmech.2024.116128_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.05.001","article-title":"In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors","volume":"361","author":"Konsoula","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2024.116128_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12936-021-03617-1","article-title":"Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones","volume":"20","author":"Chen","year":"2021","journal-title":"Malar. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:15:48Z","timestamp":1722910548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":56,"alternative-id":["S0223523424000084"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116128","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116128"}}